Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA Scientific Sessions 2023 Late-Breaking Science Coverage
Author(s): Alexander Fanaroff Added: 5 months ago
Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of… View more

Vascular Disease and Surgery

Heart Failure
AF, Stent and Anticoagulant
Author(s): Balen Abdulrahman , Richard J Jabbour , Nick Curzen Added: 10 months ago

Anticoagulation

Standards & Guidelines
ESC 22: Hot Line & Late-breaking Science Video Collection
Author(s): John JV McMurray , Mirvat Alasnag , Purvi Parwani , et al Added: 1 year ago
What's hot at European Society of Cardiology (ESC) Congress 22? Stay tuned and browse our curated coverage of the latest data in cardiology. For a concise line up of the most awaited trials joinProf Nicolas Van MieghemandDr Joost Daemen and their regular View From the Thoraxcenter series. For a deeper dive into key clinical trial data and applicability, host, Dr Harriette Van Spall… View more

Anticoagulation

Standards & Guidelines
TCT 23: Late-Breaking Clinical Trials Revealed
Added: 6 months ago Source:  Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in… View more
Author(s): Paul Guedeney , Birgit Vogel , Roxana Mehran Added: 3 years ago
Dual antiplatelet therapy (DAPT) including aspirin and a P2Y12 inhibitor is the current gold standard for the treatment and mid-term secondary prevention of acute coronary syndrome (ACS).1–4 However, despite the use of potent P2Y12 inhibitors such as ticagrelor or prasugrel, patients remain at high ischaemic risk after ACS. More specifically, in the prasugrel treatment arm of the TRial to Assess… View more

Anticoagulation

MI/ACS
Author(s): Jean-Philippe Collet Added: 3 years ago
The role of platelets in coronary artery thrombosis is well-established.1 They also play a critical role in a number of cardiovascular conditions including stroke, peripheral vascular disease and diabetes, and may be involved in the pathology underlying atherosclerotic changes.1 Antiplatelet agents such as clopidogrel, a platelet P2Y12 receptor antagonist, and aspirin are used for the prevention… View more

Anticoagulation

Vascular Disease and Surgery
Immediate Impact Without the Need for Thrombolytics in the Treatment of Acute Pulmonary Embolism
Author(s): Felix Mahfoud , Nils Kucher Added: 1 year ago
Pulmonary Embolism is a common disease with a challenging diagnosis. It is the third leading cause of cardiovascular mortality after heart attack and stroke. Despite high mortality rates, anticoagulation alone remains the mainstay treatment for nearly half of the patients diagnosed with PE. 20-50% of them have residual thrombus after receiving conservative treatment, developing life limiting… View more

Prevention & Chronic Conditions

Intervention
Anti-thrombotic Therapy Following TAVI: UK and Ireland Consensus Statement
Author(s): Azfar Zaman , Bernard Prendergast , David Hildick-Smith , et al Added: 1 year ago

Anticoagulation
Author(s): Joelle Kefer Added: 3 years ago
Atrial septal abnormalities are common congenital lesions remaining asymptomatic until adulthood in a great number of patients. The most frequent atrial septal defects in adults are ostium secundum atrial septal defect (ASD) and patent foramen ovale (PFO), both approachable by transcatheter closure using device implantation. The first non-surgical ASD closure was performed in 1975 by Mills and… View more

Vascular Disease and Surgery

Intervention
Antithrombotic Therapy after Percutaneous Coronary Intervention
Author(s): Darshni Arishta Jhagroe , Jur ten Berg Added: 3 years ago
Dual antiplatelet therapy (DAPT) is indicated in patients who need to undergo percutaneous coronary intervention (PCI) procedures.1 Compared with oral anticoagulation (OAC) and aspirin, DAPT has been shown to reduce the risk of thrombotic events and the rate of bleeding events.2 Chronic OAC is required in up to 10 % of the patients undergoing PCI, and is usually indicated for AF and mechanical… View more

Anticoagulation

Intervention